AI-generated summary
The authors compared two regimens for rosacea, both including oral doxycycline: one with the Shumin treatment instrument and one with red light therapy, over 12 weeks in 60 patients. They report a higher efficacy rate with the Shumin device (93.3% versus 80.0%), greater quality-of-life improvement, and a lower relapse rate, with a favorable safety profile.
- Participants
- 60
- Who or what was studied
- Patients with rosacea
- Limits stated in the abstract
- The abstract does not describe blinding or the statistical basis for the efficacy comparison, and the study is preliminary, with no reported method for randomization or allocation concealment.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Objective
This study aimed to compare the clinical efficacy and safety of two rosacea treatment regimens: oral doxycycline plus the Shumin treatment instrument and oral doxycycline plus red light therapy. Objective assessments, including reflectance confocal microscopy, were used to evaluate both regimens.
Materials And Methods
A total of 60 patients with rosacea were randomly divided into two groups, each containing 30 patients. The control group received doxycycline (100 mg/day) orally combined with red light therapy for 12 weeks (twice a week), whereas the experimental group received doxycycline (100 mg/day) orally combined with Shumin treatment instrument therapy for 12 weeks (twice a week).
Results
The efficacy rate was 93.3% in the experimental group and 80.0% in the control group. Following treatment, significant reductions in Dermatology Life Quality Index scores and Demodex counts were achieved in both groups (all p < 0.001). However, the experimental group exhibited superior improvements in Dermatology Life Quality Index scores and affected hair follicle counts compared with the control group (p < 0.05). No significant difference was observed in the reduction in the total Demodex count between the groups. Similarly, no significant difference was observed in the change in the total hair follicle number between the groups. Furthermore, the relapse rate was notably lower in the experimental group than in the control group (p = 0.026).
Conclusion
When used as an adjunctive therapy with oral doxycycline, the Shumin device yields better clinical outcomes than red light therapy for treating rosacea and has a favorable safety profile. These preliminary results establish a basis for the use of adjuvant physical interventions for rosacea.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Control group, Red light therapy. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.